Metastatic lung cancer is lung cancer that has spread beyond the lungs to other parts of the body. It’s classified as stage IV, the most advanced stage, and it’s the most common presentation at diagnosis: roughly 52% of lung cancers are already metastatic when first detected. The five-year relative survival rate for metastatic lung cancer is 9.7%, though that number is improving as newer treatments become available.
Where Lung Cancer Spreads
Lung cancer cells can break away from the original tumor, travel through the bloodstream or lymphatic system, and settle in distant organs. The destination depends partly on the type of lung cancer. In non-small cell lung cancer (NSCLC), the most common type, the brain is the top site of spread at 29%, followed by bone (25%), adrenal glands (15%), and liver (13%). Small cell lung cancer follows a slightly different pattern, favoring the liver first (33%), then the brain (30%) and bone (27%).
The adrenal glands, small hormone-producing organs sitting on top of each kidney, are a surprisingly frequent target. Cancer can also spread to the skin, the lining around the heart, and other less common locations. Many people develop metastases in more than one organ simultaneously.
Symptoms by Location
The symptoms of metastatic lung cancer depend heavily on where the cancer has traveled. You may still have lung-related symptoms like coughing, shortness of breath, or chest pain, but new symptoms from distant sites often signal that the disease has spread.
- Brain: Headaches, dizziness, memory problems, sleepiness, seizures, or numbness and weakness in an arm or leg.
- Bone: Pain (often in the back or hips), unexpected fractures from weakened bone structure.
- Liver: Yellowing of the skin and eyes (jaundice), swelling in the abdomen.
- Adrenal glands: Typically no symptoms unless the tumor grows large enough to cause abdominal or back pain.
Because adrenal metastases are often silent, they’re frequently discovered during imaging scans rather than from symptoms you’d notice on your own.
How It’s Diagnosed
Confirming metastatic lung cancer usually involves imaging (CT scans, PET scans, MRI of the brain) combined with a biopsy of the tumor tissue. The biopsy isn’t just to confirm cancer. It’s also tested for specific genetic mutations and protein markers that determine which treatments are most likely to work.
For some patients, a blood draw called a liquid biopsy can identify tumor DNA circulating in the bloodstream. This is especially useful when a tumor is hard to reach with a needle or when doctors need to track how the cancer’s genetic profile changes over time. In advanced lung cancer, liquid biopsy performs well for detecting certain mutations, with sensitivity reaching up to 83% and specificity around 90% compared to traditional tissue biopsy. It’s not a replacement for tissue biopsy in every situation, but it’s become a valuable complement.
Treatment With Immunotherapy
Immunotherapy has transformed the treatment landscape for metastatic lung cancer over the past decade. These drugs work by removing the “brakes” that cancer cells put on your immune system, allowing your own immune cells to recognize and attack the tumor.
The specific approach depends on a protein called PD-L1, which is measured in the tumor. If PD-L1 levels are high, immunotherapy alone may be enough as a first treatment. For patients with lower PD-L1 levels, immunotherapy is typically combined with chemotherapy. Some regimens pair two different types of immune-stimulating drugs together, one that blocks a checkpoint called PD-1 and another that blocks a checkpoint called CTLA-4, to activate the immune response through two pathways at once. These combinations are sometimes given with chemotherapy as well, depending on the clinical situation.
Not everyone responds to immunotherapy, and side effects can include fatigue, skin reactions, and inflammation in various organs as the immune system becomes more active. But for patients who do respond, the benefits can be durable in ways that chemotherapy alone rarely achieved.
Targeted Therapy for Specific Mutations
About a quarter of NSCLC tumors carry genetic mutations that can be directly targeted with oral medications. This is why molecular testing of the tumor is so important. If your cancer has one of these mutations, targeted therapy is typically more effective than chemotherapy or immunotherapy.
The most well-known targetable mutation involves a gene called EGFR. Several generations of drugs have been developed for EGFR-positive lung cancer, with newer versions designed to overcome resistance that develops to earlier ones. Another mutation, ALK rearrangement, occurs in roughly 3 to 8% of NSCLC cases and has multiple approved treatment options. A mutation in the KRAS gene, present in about 13% of NSCLC patients, was long considered untreatable because the protein lacked a good binding site for drugs. That changed recently with the approval of a new class of inhibitors specifically designed for one form of this mutation.
Other less common but targetable mutations include ROS1 fusions, BRAF mutations, and NTRK gene fusions. Each has its own approved therapy. The key takeaway: comprehensive genetic testing at diagnosis can open treatment doors that wouldn’t exist otherwise.
Managing Brain Metastases
Brain metastases deserve special attention because they’re so common in lung cancer and carry significant quality-of-life implications. Treatment options include surgery (when the tumor is accessible and limited in number), stereotactic radiosurgery, and whole-brain radiation.
Stereotactic radiosurgery isn’t actually surgery. It uses many precisely aimed radiation beams that converge on the tumor, delivering a high dose to cancer cells while largely sparing surrounding brain tissue. It’s typically done in one to five sessions. Whole-brain radiation treats the entire brain over 10 to 15 sessions spread across two to three weeks. It’s more commonly used when there are multiple brain metastases. Side effects can include fatigue, nausea, headache, and hair loss. Steroids are often prescribed alongside these treatments to reduce brain swelling and ease symptoms like headaches and neurological problems.
Protecting Bones From Further Damage
Bone metastases don’t just cause pain. They can lead to serious complications: fractures through weakened bone, spinal cord compression, and the need for emergency stabilization surgery. To reduce these risks, doctors often prescribe bone-strengthening medications that slow the breakdown of bone tissue. These are given as injections, typically every few weeks, and can meaningfully reduce the chance of fractures and other bone-related emergencies over time.
Why Early Palliative Care Matters
Palliative care is often misunderstood as end-of-life care. In reality, it’s specialized medical care focused on relieving symptoms and improving quality of life, and it works best when started early alongside cancer treatment, not as a last resort.
A landmark study published in the New England Journal of Medicine found that patients with metastatic NSCLC who received palliative care starting soon after diagnosis scored significantly higher on quality-of-life measures than those who received standard care alone. Rates of depression were dramatically lower: 16% in the early palliative care group compared to 38% in the standard care group. Perhaps most striking, patients who received early palliative care actually lived longer, with a median survival of 11.6 months versus 8.9 months, even though they received less aggressive interventions near the end of life.
Palliative care teams help manage pain, breathing difficulties, nausea, fatigue, anxiety, and the practical challenges of living with advanced cancer. This support runs alongside your oncology treatment, not instead of it.